Frontlight ResearchEarly access
Active, not recruitingNo phase
tRNS Treatment for ADHD Symptoms
Key facts
- Who runs it
- Innosphere
- Where
- Boston, Houston, and Rochester, United StatesSee the 4 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 146 people, planned
- Started
- 15 Jul 2024
- Ended
- 30 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- tRNS
- Record updated
- 17 February 2026
Who can take part
- Age
- 7 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age between 7-12 years old at the time of enrollment
- Estimated Full Scale IQ ≥ 85 based on WASI-II (Two-subtests Form) NOTE: Results of an equivalent and validated IQ test that were performed in the previous 12 months from the date of enrollment are acceptable. The Investigator must ensure that no significant head injuries, particularly significant head trauma, occurred in this period from the previous test to the enrollment
- Score above the standard clinical cut-off score for ADHD symptoms on the ADHD DSM-5 scales
- Meet criteria for ADHD according to DSM-5, using the "gold standard" procedure as described by the American Academy of Pediatrics, which includes a semi-structured interview of the subject and parent(s)/legal guardian(s)
- Moderate to severe ADHD as defined as having a minimum score of 12 on either the inattention subscale or the and hyperactivity-impulsivity subscale of the baseline ADHD Rating Scale (ADHD-RS), and a Clinical Global Impression-Severity (CGI-S) score at baseline of greater than 4
- Parent(s)/legal guardian(s) fluent in English, able to complete ADHD-RS scale and attend all study visits
- Has not taken any medication with central nervous system effects, including prescription medications for ADHD, within 7 days of enrollment, as determined by the investigator based on the subject's medical history from the parent(s)/legal guardian(s) and, as applicable, medical and pharmacy records
Who cannot take part
- Impaired functioning to a degree that requires immediate initiation of ADHD medication in the opinion of the Investigator
- Has a history of any medical or psychiatric disorder, disease, condition, injury, symptoms or circumstance that, in the opinion of the principal investigator, may: (1) reduce the subject's ability to fulfill the study requirements as per protocol; or (2) adversely impact the integrity of the data or the validity of the study results
- Primary DSM-5 axis-1 disorder other than ADHD, which consists of one or more of severe ODD, bipolar psychosis, major depressive disorder, severe oppositional defiant disorder that would pose adherence challenges by the investigator
- Known hypersensitivity to Polyamide or Elastomer
- Any other condition, which would make the participant unsuitable to participate in this study as determined by the Investigator
- Any suicide risk as assessed with the Columbia-Suicide Severity Rating Scale (Pediatric (≤11 years) Quick Screen)
- Substance abuse, that, in the opinion of the investigator, may: (1) reduce the participant's ability to fulfill the study requirements as per protocol; or (2) adversely impact the integrity of the data or the validity of the study results
- If female, began menstruation, based on a self- or parent(s)/legal guardian(s)-report
- Inability to provide informed consent and assent (participant and parent(s)/legal guardian(s))
Where in United States
Also in 1 other country, 1 site
- Boston Children's HospitalBoston, United States
- Baylor College of Medicine Department of Psychiatry & Behavioral SciencesHouston, United States
- UTHealth HoustonHouston, United States
- Mayo Clinic Hospital - Methodist CampusRochester, United States
About the trial
What the trial wants to find out
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.
The 2 groups in the trial
- Group A: Treatment ArmExisting treatment, for comparison
The same device placement will be used for sham as in the active arm.
Treatment: tRNS
- Group B: Sham-Control ArmSham treatment, for comparison
The same device placement will be used for sham as in the active arm.
Treatment: tRNS
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 February 2026